Publications (4)1.13 Total impact
- 01/2014; 3(8):1. DOI:10.5455/ijmsph.2014.180620143
- 12/2013; 4(11):823. DOI:10.7439/ijbar.v4i11.529
- [Show abstract] [Hide abstract]
ABSTRACT: High levels of glycated hemoglobin (HbA(1c)) have been associated with Coronary Vascular Diseases (CVD) in diabetic patients. Recent studies have reported no association between elevated glycated hemoglobin (HbA(1c)) and incident cardiovascular disease (CVD) among women without diabetes. There are many controversial studies on topics such as "Glycated hemoglobin levels (HbA(1c)) have been associated with cardiovascular diseases (CVD) in the non-diabetic patients". Therefore, we planned this study. The present study was conducted on 50 age matched controls and 50 clinically diagnosed non-diabetic CVD patients of either gender. The study included 50 patients with myocardial infarction (MI) admitted to the ICCU ward of J.L.N. Medical College and Hospital, Ajmer (Rajasthan). The following information was recorded from admission sheets of non-diabetic CVD patients of either gender: history of diabetes, hypertension, and cigarette smoking; demographic indices; coronary heart disease and diabetes mellitus treatment; serum cholesterol; serum triglycerides (TG); high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C); fasting and non-fasting blood glucose levels and Glycated haemoglobin levels (HbA(1c)). Glycosylated hemoglobin (HbA(1c)) was measured by latex agglutination inhibition assay. The HbA(1c) levels in healthy controls (n = 50) and non-diabetic CVD subjects (n = 50) observed were 4.32 +/- 0.34% and 5.80 +/- 0.20%, respectively. HbA(1c) levels in these subjects were significantly higher than controls (p < 0.001). The HbA(1c) levels in non-diabetic CVD patients are higher in comparison to controls.Clinical laboratory 01/2011; 57(7-8):517-22. · 1.13 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Inflammatory reactions in coronary plaques play an important role in the pathogenesis of acute atherothrombotic events; inflammation elsewhere is also associated with both atherogenesis generally and its thrombotic complications. The aim of study was to investigate the predictive value of Hs-CRP (high sensitivity C-reactive protein) in coronary heart disease (CHD).The study population contained 200 subjects divided into two groups, 150 patients with CHD and 50, age and sex matched healthy control subjects. Hs-CRP is a marker of inflammation in coronary heart disease. The level of CRP in the serum samples was estimated by a high sensitivity immunoturbidometric assay. Hs-CRP, total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL) levels, were found significantly high in coronary heart disease patients as compared to healthy subjects but significant decrease in high density lipoprotein cholesterol (HDL-C) in CHD patients as compared to healthy controls. In conclusion, our study shows a significant increase in Hs-CRP, TC, TG, LDL-C and VLDL-C in the circulation of coronary heart disease patients. A significant decrease in levels of HDL-C was observed only in CHD patients. The concentration of Hs-CRP (inflammatory marker) is increased in coronary heart disease subjects. Therefore these biomarkers may be useful in diagnosis of coronary heart disease. INTRODUCTION Inflammation plays a role in the development of atherosclerosis and coronary heart disease (Lind, 2003). Elevated markers of inflammation, in particular CRP, are associated with an increased risk of future cardiovascular events in healthy subjects, in patients with stable or unstable coronary artery disease and acute myocardial infarction (Buffon et al., 2002; Zairis et al., 2002). The most common cause of coronary heart disease is atherosclerosis with erosion or rupture of a plaque causing transient, partial or complete arterial occlusion. Heart cannot continue to function without adequate blood flow, and if it is severely compromised, death is inevitable. Several risk factors for coronary heart disease have been well documented, including hypertension, hyperlipidemia, diabetes, a positive family history of CHD, smoking, obesity and physical inactivity (Kasap et al., 2007). C-reactive protein (CRP) is the prototype acute-phase protein primarily synthesized in the liver and its release is stimulated by interleukin 6 (IL-6) and other pro inflammatory cytokines (Daniel et al., 2003). Composed of five 23 kDa subunits, C-reactive protein (CRP) is a hepatically derived pentraxin that plays a key role in the innate immune response. CRP has a long plasma half-life and is now understood to be a mediator as well as a marker of atherothrombotic disease. High sensitive CRP (Hs-CRP) has been shown to have prognostic value in patients with acute coronary syndromes; however, the most promising use of Hs-CRP has been in the primary prevention setting. Hs-C-reactive protein not only may be a marker of low grade chronic systemic inflammation but also may be directly involved in atherosclerosis (Ridker et al., 2003). It can amplify the anti-inflammatory response through complement activation, tissue damage, and activation of endothelial cells (Libby et al., 2002). In the present communication, we assessed the high sensitivity C-reactive protein in patients with coronary heart disease with age and sex matched healthy subjects.